Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Agenus 3.05 0.16 5.54% -8.96%
Alnylam Pharmaceuticals 148.50 0.50 0.34% -10.74%
Amgen 235.36 4.51 1.95% -4.13%
Arrowhead Research 57.81 0.23 0.40% -28.40%
Biogen 239.30 2.63 1.11% -13.25%
Bluebird Bio 8.73 0.21 2.46% -82.72%
Dicerna Pharmaceuticals 38.22 0.22 0.58% 71.54%
Exelixis 18.12 0.35 1.97% -23.62%
Gilead Sciences 71.77 -0.11 -0.15% 13.33%
GlaxoSmithKline 1,707.80 66.80 4.07% 21.99%
Intercept Pharmaceuticals 17.76 1.31 7.96% -35.30%
Immunogen 6.49 0.03 0.46% -9.99%
Ionis Pharmaceuticals 33.08 0.95 2.96% -46.02%
Karyopharm Therapeutics 8.04 0.01 0.12% -46.18%
Lexicon Pharmaceuticals 3.45 0.06 1.77% -49.78%
MacroGenics 14.44 0.41 2.92% -29.87%
Merck & Co 81.38 0.06 0.07% -2.40%
Mirati Therapeutics 124.31 5.57 4.69% -42.04%
Pfizer 54.95 -0.59 -1.06% 49.73%
Ultragenyx Pharmaceutical 72.05 2.16 3.09% -47.78%
Regeneron Pharmaceuticals 615.24 -0.87 -0.14% 18.79%
Regulus Therapeutics 0.25 -0.01 -4.45% -79.24%
Roche Holding 367.35 2.35 0.64% 16.64%
Acceleron Pharma 178.75 -0.93 -0.52% 57.43%
Intrexon 3.23 0.15 4.87% -59.68%

Indexes Price Day Year
NASDAQ 14894 86.94 0.59% 14.58%
US2000 2162 3.02 0.14% 1.85%

Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It is focused on development of RNAi-based therapeutics using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases. Its development programs include dacryocystorhinostomy (DCR)-PHXC for the treatment of primary hyperoxaluria (PH), which is in a Phase I clinical trial; DCR-HBVS for the treatment of chronic hepatitis B virus (HBV), which is in a Phase I clinical trial, and a product candidate against a rare liver disease. It also developed a wholly owned clinical candidate, DCR-BCAT, targeting the ß-catenin oncogene. DCR-BCAT is delivered by its lipid nanoparticle (LNP) tumor delivery system, EnCore.